Old Web
English
Sign In
Acemap
>
authorDetail
>
D. Damek
D. Damek
University of Colorado Boulder
Radiology
Temozolomide
Glioblastoma
Medicine
Bevacizumab
3
Papers
2
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Hypofractionated–Intensity Modulated Radiation Therapy (Hypo-IMRT) and Temozolomide (TMZ) With and Without Bevacizumab (BEV) for Glioblastoma Multiforme (GBM): A Comparison of 2 Prospective Phase 2 Trials
2014
International Journal of Radiation Oncology Biology Physics
J.A. Carlson
K. Reddy
Laurie E. Gaspar
D. Ney
Brian D. Kavanagh
D. Damek
Kevin O. Lillehei
C. Chen
Show All
Source
Cite
Save
Citations (1)
A Phase 2 Trial of Hypofractionated–Intensity Modulated Radiation Therapy (Hypo-IMRT) Combined With Temozolomide (TMZ) and Bevacizumab (BEV) for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
2014
International Journal of Radiation Oncology Biology Physics
J.A. Carlson
D. Ney
K. Reddy
Laurie E. Gaspar
Brian D. Kavanagh
D. Damek
Kevin O. Lillehei
C. Chen
Show All
Source
Cite
Save
Citations (0)
Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme
2011
International Journal of Radiation Oncology Biology Physics
K. Reddy
D. Damek
Laurie E. Gaspar
D. Ney
Brian D. Kavanagh
A. Waziri
Kevin O. Lillehei
Kelly Stuhr
Changhu Chen
Show All
Source
Cite
Save
Citations (1)
1